What is Schwartz-Jampel syndrome

Schwartz-Jampel syndrome is a rare genetic disorder characterized by permanent muscle stiffness (myotonia), skeletal abnormalities, and distinctive facial features. It is caused by mutations in the HSPG2 gene, which affects the function of perlecan, a protein essential for the stability and signaling of muscle and cartilage tissues.

What are the primary symptoms and body systems affected by Schwartz-Jampel syndrome?

Schwartz-Jampel syndrome primarily impacts the musculoskeletal system. The hallmark symptom is myotonia, or continuous muscle activity, which prevents muscles from relaxing properly after contraction. This leads to a stiff, characteristic gait and difficulty opening the eyelids fully (blepharophimosis). Skeletal involvement often manifests as short stature, spinal curvature (scoliosis or kyphosis), and joint contractures that limit range of motion. Other common features of Schwartz-Jampel syndrome include a small, puckered mouth, low-set ears, and a high-pitched voice due to laryngeal muscle involvement.

How is Schwartz-Jampel syndrome classified and how common is it?

The condition is generally categorized into two main types based on the severity and age of onset: Type 1 (the classic form) and Type 2 (often considered a more severe variant, sometimes overlapping with Stuve-Wiedemann syndrome). Schwartz-Jampel syndrome is an extremely rare condition, with fewer than 100 cases reported in medical literature worldwide. Because it is so rare, exact prevalence numbers are difficult to establish, though it affects both males and females equally. At DiseaseMaps.org, 16 individuals have joined our community to share their experiences, highlighting the importance of global collaboration for this rare diagnosis.

What causes Schwartz-Jampel syndrome and is it hereditary?

Schwartz-Jampel syndrome is a genetic disorder inherited in an autosomal recessive pattern. This means an individual must inherit two copies of the mutated HSPG2 gene—one from each parent—to manifest the disease. The HSPG2 gene provides instructions for producing perlecan, a protein found in the basement membranes of various tissues. When perlecan is dysfunctional, it disrupts the communication between nerves and muscles, leading to the clinical manifestations of Schwartz-Jampel syndrome.

How is Schwartz-Jampel syndrome distinguished from other conditions?

While many neuromuscular disorders involve muscle weakness, Schwartz-Jampel syndrome is distinct because it is primarily defined by muscle stiffness and skeletal dysplasia rather than progressive muscle wasting. Clinicians differentiate it from other myotonic disorders by looking for these specific diagnostic indicators:

• Myotonia: Persistent muscle contraction that does not relax.


• Skeletal Dysplasia: Distinctive bone structure abnormalities and short stature.


• Facial Dysmorphism: Specific facial features like blepharophimosis and a small, puckered mouth.


• Genetic Confirmation: Molecular testing identifying biallelic mutations in the HSPG2 gene.

Next steps

• Consult with a clinical geneticist to confirm a diagnosis through molecular genetic testing.


• Schedule an evaluation with a pediatric neurologist or a neuromuscular specialist to manage myotonia and muscle stiffness.


• Connect with the community at DiseaseMaps.org to share experiences with the 16 other members navigating Schwartz-Jampel syndrome.


• Work with a physical therapist specializing in rare musculoskeletal disorders to help maintain joint mobility and manage contractures.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of a qualified healthcare provider with any questions regarding a medical condition.

References

• Orphanet: Schwartz-Jampel syndrome (ORPHA:802).


• NIH Genetic and Rare Diseases Information Center (GARD): Schwartz-Jampel syndrome.


• OMIM (Online Mendelian Inheritance in Man): Schwartz-Jampel syndrome (Entry #255800).


• PubMed: Clinical and molecular characterization of patients with Schwartz-Jampel syndrome.